Broadfin Capital’s Intersect ENT, Inc XENT Stock Holding History

Broadfin Capital’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$15.7M	Sell	631,023 -148,111	-19%	-$3M	2.1%	13
2019 Q3	$13.3M	Buy	+779,134	New	+$14.2M	2.45%	11
2019 Q2	–	Sell	-263,500	Closed	-$8.47M	–	49
2019 Q1	$8.47M	Sell	263,500 -24,400	-8%	-$755K	1.75%	21
2018 Q4	$8.11M	Buy	287,900 +53,700	+23%	+$1.57M	1.07%	28
2018 Q3	$6.73M	Buy	+234,200	New	+$7.03M	0.99%	29
2016 Q4	–	Sell	-638,600	Closed	-$10.1M	–	73
2016 Q3	$10.1M	Sell	638,600 -72,000	-10%	-$1.08M	0.91%	34
2016 Q2	$9.19M	Buy	+710,600	New	+$11.1M	0.89%	29

Other funds holding XENT

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Broadfin Capital's XENT Position: Q4 2019 in Review

Broadfin Capital reduced its Intersect ENT, Inc (XENT) stake by 19% in Q4 2019, selling an estimated $3M and leaving 631,023 shares worth $15.7M. The position accounts for 2.1% of the portfolio, ranked #13.

Broadfin Capital first reported a position in XENT in Q2 2016 and has held it in 7 quarters since. 120 funds tracked by Wall St. Rank hold XENT as of Q4 2019.

Broadfin Capital held 631,023 shares of Intersect ENT, Inc worth $15.7M as of Q4 2019.
Broadfin Capital sold 148,111 Intersect ENT, Inc shares in Q4 2019, an estimated $3M.
Intersect ENT, Inc made up 2.1% of Broadfin Capital's portfolio in Q4 2019, its #13 holding.
Broadfin Capital first reported a position in Intersect ENT, Inc in Q2 2016 and has held it in 7 quarters since.
120 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.